This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mato, E. Articles by de Leiva, A. Search for Related Content PubMed PubMed Citation Articles by Mato, E. Articles by de Leiva, A.

Somatostatin and Somatostatin Receptor Subtype Gene Expression in Medullary Thyroid Carcinoma¹

Departments of Endocrinology (A.C., E.M., S.M.W., R.C., A.d.L.), Pathology (X.M.-G.), and Nuclear Medicine (L.B.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona 08025, Spain

Address all correspondence and requests for reprints to: Eugenia Mato, Ph.D., Department of Endocrinology, Hospital de Sant Pau, Av.S.Antoni M^aClaret n°167, Barcelona 08025, Spain. E-mail: emato{at}santpau.es

The possible existence of an autocrine/paracrine role for SRIF in normal and neoplastic thyroid parafollicular C cells has supported the use of SRIF analogues in the treatment of patients with medullary thyroid carcinoma (MTC). In this study, we have investigated the expression of SRIF by immunohistochemistry and RT-PCR, and the expression of SRIF receptor (SSTR) subtypes by RT-PCR, in a series of 14 MTCs. SRIF messenger RNA was detected in all cases, although immunoreactive cells were only identified in 8. SSTR messenger RNA was present in 12 out of the 14 tumors. Expression of more than 1 SSTR subtype was detected in 10 tumors. SSTR2, the subtype that preferentially binds to the SRIF analogue octreotide, was the subtype most frequently detected, whereas SSTR4 was not detected in any case. These results confirm the frequent expression of both SRIF and its receptors in MTC. The presence of different combinations of SSTR subtypes in a given patient may explain the variable clinical response to SRIF analogues and may promote the search for more selective drugs with different affinities to the various receptor subtypes.

This article has been cited by other articles:

				E Thodou, G Kontogeorgos, D Theodossiou, and M Pateraki Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J. Clin. Pathol., March 1, 2006; 59(3): 274 - 279. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				M. C. Zatelli, F. Tagliati, J. E. Taylor, R. Rossi, M. D. Culler, and E. C. degli Uberti Somatostatin Receptor Subtypes 2 and 5 Differentially Affect Proliferation in Vitro of the Human Medullary Thyroid Carcinoma Cell Line TT J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2161 - 2169. [Abstract] [Full Text]

				A. Lacroix, N. N'Diaye, J. Tremblay, and P. Hamet Ectopic and Abnormal Hormone Receptors in Adrenal Cushing's Syndrome Endocr. Rev., February 1, 2001; 22(1): 75 - 110. [Abstract] [Full Text]

				N. Baou, M. Bouras, J.-P. Droz, M. Benahmed, and S. Krantic Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type Carcinogenesis, April 1, 2000; 21(4): 805 - 810. [Abstract] [Full Text] [PDF]

				X. Matias-Guiu Mixed Medullary and Follicular Carcinoma of the Thyroid : On the Search for Its Histogenesis Am. J. Pathol., November 1, 1999; 155(5): 1413 - 1418. [Full Text] [PDF]